title: Prognostic factors for response to chemotherapy containing platinum derivatives in patients with unresectable non-small cell lung cancer. (NSCLC).
abstract: OBJECTIVE
  To identify pretreatment variables predicting response to platinum derivatives containing chemotherapy in patients with unresectable non-small cell lung cancer (NSCLC).
  
  
  METHODS
  Eligible patients included in one of the 7 consecutive clinical trials conducted by the European Lung Cancer Working Party between December 1980 and August 1991. All patients received a cisplatin or carboplatin containing chemotherapy. We analyzed 22 potential prognostic factors including sex, age, histology, performance status, weight loss, type of lesions, extent of disease, main metastatic sites and several biological parameters, namely white blood cell count (WBC), neutrophil count, platelet count, hemoglobinemia, creatininemia, serum alkaline phosphatases and LDH.
  
  
  RESULTS
  On 1052 eligible patients. 107 were not assessable for response. The objective response rate was 26% (95% C.I.: 23, 29%). Univariate analysis identified as statistically significantly associated with a higher objective antitumoral response rate the following characteristics: a normal platelet count, the absence of skin metastasis, the absence of adrenal metastasis, a higher creatininemia, a normal hemoglobinemia, an older age and a normal WBC count. On a restricted set of variables including data from 777 patients, a multivariate logistic regression model disclosed age and platelet count as significantly and independently related to response rate.
  
  
  CONCLUSIONS
  Clinical and demographic characteristics of patients with unresectable NSCLC, as well as routine laboratory parameters, could not accurately predict response to chemotherapy in a population of patients selected for a clinical trial. Future studies on this subject should include more sophisticated variables as new biomolecular makers.
authors.affiliation: Service de Médecine, Institut Jules Bordet, Bruxelles, Belgium.
authors.forename: M
authors.initials: M
authors.lastname: Borges
authors.forename: J P
authors.initials: JP
authors.lastname: Sculier
authors.forename: M
authors.initials: M
authors.lastname: Paesmans
authors.forename: M
authors.initials: M
authors.lastname: Richez
authors.forename: G
authors.initials: G
authors.lastname: Bureau
authors.forename: G
authors.initials: G
authors.lastname: Dabouis
authors.forename: J
authors.initials: J
authors.lastname: Lecomte
authors.forename: J
authors.initials: J
authors.lastname: Michel
authors.forename: O
authors.initials: O
authors.lastname: Van Cutsem
authors.forename: J
authors.initials: J
authors.lastname: Schmerber
authors.forename: V
authors.initials: V
authors.lastname: Giner
authors.forename: M C
authors.initials: MC
authors.lastname: Berchier
authors.forename: R
authors.initials: R
authors.lastname: Sergysels
authors.forename: P
authors.initials: P
authors.lastname: Mommen
authors.forename: J
authors.initials: J
authors.lastname: Klastersky
mesh_terms: D000328:Adult; D000368:Aged; D000970:Antineoplastic Agents / Q000627:therapeutic use*; D015415:Biomarkers; D016190:Carboplatin / Q000627:therapeutic use*; D002289:Carcinoma, Non-Small-Cell Lung / Q000188:drug therapy* / Q000378:metabolism / Q000473:pathology; D002945:Cisplatin / Q000627:therapeutic use*; D005260:Female; D006801:Humans; D016015:Logistic Models; D008175:Lung Neoplasms / Q000188:drug therapy* / Q000378:metabolism / Q000473:pathology; D008297:Male; D008875:Middle Aged; D015999:Multivariate Analysis; D009367:Neoplasm Staging; D011379:Prognosis; D016896:Treatment Outcome
chemical_list: D000970:Antineoplastic Agents; D015415:Biomarkers; D016190:Carboplatin; D002945:Cisplatin